Mesothelioma Survival Rates by Stage and Histology: What the Trial Data Actually Show

The first thing many people do after being told their mesothelioma stage is search the stage and “survival.” The number that comes back is almost always pulled from a population dataset, presented without context, and read as a personal prognosis. It is rarely either of those things.

This guide is for someone who wants to understand what the published mesothelioma survival numbers actually measure, where the numbers come from, and what changes them. It draws on the SEER program at the National Cancer Institute, the IASLC Mesothelioma Staging Project, and the two pivotal modern first-line trials (CheckMate-743 and IND.227 / KEYNOTE-483). It does not produce a personal estimate. The data does not support that. It does help frame the conversation with your oncology team.

For broader context on mesothelioma and the treatment options that change these numbers, see the linked overviews. This article is the survival-data companion to the first-line treatment decision guide and to the late-stage symptom management guide.

Why Stage-Only Survival Numbers Can Mislead

A “stage 3 mesothelioma 5-year survival” search returns numbers from many different sources mixed together. They look like one statistic. They are not.

Three things change what each number actually represents:

• Which staging system was used. SEER summary stage (localized, regional, distant) is not the same as AJCC TNM stage I through IV. SEER groups disease by how far it has spread on imaging and pathology summary; TNM uses tumor extent, nodal involvement, and metastasis. A “regional” tumor in SEER often spans TNM stages II and III.
• What “survival” means in that source. Relative survival adjusts for the background mortality of an age-matched population. Observed survival does not. Median overall survival from a clinical trial reports one specific endpoint in a selected enrolled population. Five-year survival on a hospital website may be any of these three.
• Which patients are in the dataset. Trials enroll people with ECOG performance status 0 or 1, no significant interstitial lung disease, and adequate organ function. SEER captures a broad population including people who never received treatment. The same disease at the same stage produces different numbers across these datasets.

The practical consequence: a single statistic, repeated across many websites, may not describe the same population the reader is in. The numbers below are presented with their dataset, time window, and definition attached, because that context is what makes them usable.

SEER Survival Data by Stage, With Caveats

The NCI SEER program is the largest U.S. cancer surveillance dataset. SEER Cancer Stat Facts for mesothelioma, accessed 2026, reports the following 5-year relative survival figures:

• All stages combined: 12%
• Localized (confined to the pleura): 20%
• Regional (local-regional spread including nearby lymph nodes): 16%
• Distant (metastatic): 8%

These are SEER summary stages, not TNM stages. Localized is not equivalent to AJCC stage I, and distant is broader than AJCC stage IV. SEER also does not stratify by histology in the headline Stat Facts page, so the localized figure mixes epithelioid, sarcomatoid, and biphasic disease.

Cohort studies that report survival by AJCC TNM stage describe a different distribution. National Cancer Database analyses and large surgical series report median overall survival of roughly 19 to 21 months at TNM stage I, 13 to 16 months at stage III, and 9 to 12 months at stage IV. These medians come from selected cohorts, often weighted toward people who received treatment at academic centers, and are not directly comparable to the SEER 5-year figures.

The honest summary: stage-stratified survival numbers exist, but the headline figure depends on the staging system, the dataset, and the survival definition. None of them produce a personal prognosis on their own.

IASLC Mesothelioma Staging Project: Modern Stage Stratification

The IASLC (International Association for the Study of Lung Cancer) Mesothelioma Staging Project assembled the international database that underpins the AJCC 8th edition (2017) staging system and the proposed 9th edition revisions. The proposals are the most rigorously stratified survival data the field has.

The Nowak T-descriptor analysis (Journal of Thoracic Oncology, 2016) and the Rusch stage-grouping analysis (Journal of Thoracic Oncology, 2016) together generated the AJCC 8th edition criteria currently in use. These analyses showed that pleural thickness, invasion of mediastinal structures, and nodal involvement each independently predict survival, and that combining them into a stage grouping produces meaningful separation between stage I, II, III, and IV curves.

The IASLC Mesothelioma Staging Project proposals for the 9th edition (Deboever et al., Journal of Thoracic Oncology, 2024) introduce a tumor-thickness sum measurement as a quantitative complement to the T descriptor, with the goal of further refining stage I and II separation. The 9th edition is in the process of formal adoption.

For a patient, the practical content of this is straightforward: the AJCC stage is the stratification that appears on the pathology and radiology reports, and the survival differences between stages reflect real biology and treatment-eligibility differences. The 9th edition revisions add resolution at the early end of the disease, where surgical decisions are most consequential. For the AJCC primer, see our staging system overview.

Histology Stratification: Epithelioid vs Biphasic vs Sarcomatoid

Within any given stage, histology is the second major prognostic axis. Pleural mesothelioma is reported as one of three principal subtypes:

• Epithelioid: the most common, accounting for roughly 60 to 70% of cases, and historically the subtype with the most favorable outcomes.
• Sarcomatoid: the most aggressive, accounting for roughly 10 to 15% of cases, with the shortest median survival in the pre-immunotherapy era.
• Biphasic: mixed epithelioid and sarcomatoid components, with prognosis tracking the proportion of each.

Pre-immunotherapy National Cancer Database analyses reported median overall survival of approximately 14 months in epithelioid pleural mesothelioma versus approximately 4 months in sarcomatoid disease, with biphasic disease intermediate and varying by component ratio. Those medians describe an era in which the standard first-line treatment was platinum-pemetrexed chemotherapy alone.

The modern era has shifted these numbers, but unevenly. The largest single shift, by histology, is in non-epithelioid disease treated with dual checkpoint blockade. That finding, from CheckMate-743, is the reason histology now changes the first-line recommendation, not just the prognostic estimate. For a deeper background on histology, see our cell types overview.

CheckMate-743 Five-Year Update: What Immunotherapy Changes About the Curve

CheckMate-743 was a phase 3 randomized trial of 605 people with previously untreated unresectable pleural mesothelioma, comparing nivolumab plus ipilimumab against pemetrexed plus cisplatin or carboplatin. The primary publication (Baas et al., Lancet, 2021) established the survival benefit. The 5-year update (Scherpereel et al., Journal of Clinical Oncology, 2026) is the longest comparative follow-up to date.

In the intention-to-treat population, the 5-year update reports:

• 5-year overall survival: 14% with nivolumab plus ipilimumab versus 6% with chemotherapy (HR 0.74; 95% CI 0.62 to 0.88).
• Median overall survival: 18.1 months with nivolumab plus ipilimumab versus 14.1 months with chemotherapy.
• Ongoing response at 5 years: 17% of immunotherapy responders versus 0% of chemotherapy responders maintained their response.

Stratified by histology, the picture diverges:

• Epithelioid subgroup: 5-year overall survival 14% with immunotherapy versus 8% with chemotherapy (HR 0.85).
• Non-epithelioid subgroup (sarcomatoid and biphasic): 5-year overall survival 12% with immunotherapy versus 1% with chemotherapy (HR 0.48).

The non-epithelioid result is the most consequential single histology-stratified survival finding in the modern first-line literature. In a subtype that historically had a 4-month median overall survival on chemotherapy, dual checkpoint blockade produces 5-year survival in the same range as epithelioid disease. The MesoWatch coverage of the CheckMate-743 5-year update walks through the durability of response in more detail.

What the 5-year update does not do: it does not turn pleural mesothelioma into a curable disease for most patients. The 14% absolute 5-year survival means most people enrolled have died by the 5-year mark on either arm. The shape of the curve has changed. The median has moved. The plateau is small and real. Both things are true at once.

Center Volume and the Survival-Rate Caveat

Survival numbers from large mesothelioma programs differ from population-level survival numbers, and not only because the patients are different. Center volume itself is associated with outcomes in mesothelioma surgical series, as it is in other complex thoracic oncology procedures.

The published surgical series from Brigham and Women’s Hospital (Sugarbaker, Bueno), Mount Sinai (Flores), Memorial Sloan Kettering (Rusch), MD Anderson (Tsao, Hofstetter), and the University of Chicago Multidisciplinary Mesothelioma Program (Kindler, Vigneswaran) describe outcomes in carefully selected populations operated on by surgeons who do high volumes of these procedures. The medians and 5-year rates reported in those series should not be expected to generalize to a community hospital performing one or two mesothelioma surgeries a year.

The implication for survival data interpretation: the highest reported 5-year rates in the surgical literature are from centers with substantial volume and selection. They describe what is achievable in those settings, not the average outcome at any U.S. hospital. The reviewer of this guide, Dr. Anne Tsao, directs the Mesothelioma Program at the University of Texas MD Anderson Cancer Center, which is one of the high-volume centers whose outcomes shape the published surgical literature.

Practical Interpretation for Patients and Families

The most useful question to ask after a stage discussion is not “what is my survival?” It is closer to: “what does the team’s plan do to the curve I am on, and what is the next decision point?”

The published survival data answers a slightly different question. It describes what happened, on average, to a group of people enrolled in a particular study or captured in a particular registry, with their treatments and selection. The number that comes out is useful as a frame, not as a forecast.

For a person trying to make sense of their own situation, four pieces of information change which numbers apply most directly:

• Stage at diagnosis (and which staging system the team is using).
• Histology on biopsy (epithelioid, sarcomatoid, biphasic, or mixed, with the proportion if biphasic).
• Performance status (ECOG 0 or 1 versus 2 or worse changes which trial datasets describe people in a similar position).
• Treatment received and tolerated (the first-line decision is itself a major prognostic input, particularly in non-epithelioid disease).

The other thing the data shows, repeatedly, is that early-stage operable disease and late-stage inoperable disease are different conversations with different evidence bases. The cluster of stage-specific guides MesoWatch is publishing alongside this article (stage 1 operable disease, stage 3 inoperable disease, and late-stage management) is built on this distinction.

Frequently Asked Questions

The reviewer of this guide, Dr. Anne Tsao, directs the Mesothelioma Program at the University of Texas MD Anderson Cancer Center. The trial portfolio there spans first-line, second-line, and surgical investigation, and the program contributes to the international datasets that anchor much of the survival evidence cited above.